Project Grant R01DA061977
Award Date
1/15/25
Completion Date
11/30/29
Dollars Obligated
$715K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $284,040 to support research on the molecular mechanisms associated with opioid exposure in the habenula, a key brain region involved in reward processing and addiction.
The two-year project aims to: 1) map molecular changes in specific habenula cell populations in a rodent model of chronic opioid self-administration, 2) generate transcriptomic...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $275,253 to Epivario Inc., a for-profit biotechnology company, to develop a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The award supports preclinical research and drug development efforts focused on the metabolic enzyme ACSS2 and its role in regulating addiction-related memory and learning processes....
This $858,600 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to identify and validate G protein-coupled receptors (GPCRs) expressed in prefrontal cortex somatostatin-expressing inhibitory neurons (SST-INs) as potential targets for treating opioid use disorder (OUD). The research team at the University of Pittsburgh aims to take an unbiased transcriptomics approach to identify GPCR...
This $564,326 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to develop advanced statistical methods for fusing data from multiple clinical trials on medication-based treatment for opioid use disorder. The primary objectives are to: 1) create efficient estimators for average treatment effects, personalized treatment effects, and optimal individualized treatment rules using data from...
This $761,711 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a study to investigate how targeting the orexin system impacts symptoms related to neurofunctional domains associated with opioid use disorder (OUD) and insomnia. The study will use the NIDA Phenotyping Battery to deeply phenotype participants with OUD on buprenorphine, examining the effects of the dual orexin receptor antagonist...
This $175,888 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop novel statistical methods for integrating brain functional connectivity data and genetic information to better understand the neurogenetic mechanisms underlying nicotine and cannabis addiction.
Specifically, the project will:
Develop a new transcriptome-wide association study (TWAS) method to identify genes associated with both...
This Project Grant award of $195,728 from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) will support a research study to assess the acceptability and feasibility of pharmacogenomic (PGx) testing to guide opioid use disorder (OUD) treatment. The key objectives are to: 1) identify barriers and facilitators to PGx-guided OUD treatment through surveys of patients, providers, clinic staff, and administrators; 2) develop and evaluate educational...
The National Institute on Drug Abuse (NIDA) awarded Magee-Womens Research Institute and Foundation a $3,092,159 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to conduct a multimodal analysis of gestational health and placental injury in opioid-affected pregnancies. The goal is to investigate the direct impact of illicit and prescription opioids on placental development, differentiation, and function, focusing on the critical syncytiotrophoblast and...
This $399,884 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to identify small molecule compounds that can bind to the GPR26 receptor, a G-protein coupled receptor (GPCR), with the goal of restoring brain functions associated with the reward system without targeting opioid receptors. The research plan involves using a DNA-encoded library (DEL) screening approach to efficiently test a library of 125...
This Project Grant award from the National Institute on Drug Abuse (NIDA), which falls under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,536 to Chemregen Inc. to design, synthesize, and test non-opioid drug candidates to combat the opioid crisis. The key goals are to: 1) Design and synthesize lead compounds and characterize them chemically and pharmacologically, and 2) Characterize human induced pluripotent stem cell-derived neurons from normal individuals for...